Get Bravecto

Topical Flea and Tick Protection for Cats

GET BRAVECTO

Advantages

A fast-acting flea and tick protection for cats. Bravecto (fluralaner) is the feline flea control medication that is easy for pet owners to administer. Flea and tick prevention lasts up to 12 weeks* with just a single dose.

PRODUCT LABEL
  • The innovative formula is applied topically, but like the oral chew, it works systemically3
  • The Twist’n’Use™ applicator features a cap that doesn’t need to be removed3 and offers easy administration3, especially for finicky pets
  • 12-week* duration helps with the challenge of poor compliance by ensuring fewer potential gaps in protection compared to monthly topical flea control treatments
  • Available by veterinary prescription only

INDICATIONS:

Bravecto kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (black-legged tick) and Haemaphysalis longicornis (Asian longhorned tick) infestations for 12 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pounds or greater.

Bravecto is also indicated for the treatment and control of Dermacentor variabilis (American dog tick) infestations for 8 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pounds or greater.

Small cats
2.6—6.2 lbs

Medium cats
>6.2—13.8 lbs

Large cats
>13.8—27.5 lbs§

Prescribe Different Weight Bands Of Bravecto Depending On Pet’s Weight3

One application per weight

§Cats over 27.0 lb. should be administered the appropriate combination of tubes.

Bravecto®: Persistent Efficacy Against Fleas3,8,11

FAST AND PERSISTENT FLEA PROTECTION FOR 12 WEEKS

References 3,8

Flea Efficacy for Cats for Up to 12 weeks3,8

Bravecto efficacy on killing fleas and stopping flea infestations was evaluated in a 12-week multicenter, clinical field study.8 Results showed that one dose of Bravecto (fluralaner) reduced fleas by >98% within 12 hours for 12 weeks,3,8 and acts quickly, with 100% of fleas killed 8 hours after treatment.3,8 Over 12 weeks of the field study, there were 3-6x more flea-free cats with Bravecto than 3 monthly doses of Frontline® Plus.14,21 The study also found that 80% to 100% of felines with signs attributed to FAD had resolution of the following signs by the end of the study:8
  • Erythema
  • Papules
  • Crusts
  • Alopecia
  • Scales
  • Excoriation

Frontline® Plus is a registered trademark of Merial.

No items to show.

Bravecto®: The 12-Week* Difference Against Ticks3,8,11

LASTING TICK PROTECTION

References 3,8

In Cats

Bravecto (fluralaner) tick protection efficacy was evaluated in 12-week clinical field studies. Against black-legged ticks, Bravecto had >94% effectiveness 48 hours post-infestation for 12 weeks, and had >98% effectiveness against American dog ticks 48 hours post-infestation for 8 weeks.3,8

No items to show.

Hear How Veterinarians Are Breaking The Flea Lifecycle With Bravecto®

video cover

Dr. Craig Prior

Tennessee
“Bravecto goes a long way in solving clients’ flea and tick problems, so they’ll keep coming back to the clinic.”

Watch
video cover

Dr. Dan Markwalder

Illinois
“Bravecto is a popular choice among pet owners and the compliance numbers back it up.”

Watch
video cover

Dr. Randal Bennett

Texas
“Bravecto gives pet owners the joy of a flea and tick-free household.”

Watch
View More testimonials
Submit your testimonial

Bravecto is Proven Safe1-3,7,8,17,18

DOGS

Bravecto has been evaluated for use in breeding, pregnant, and lactating female dogs.1,2 Bravecto is safe to use and efficacious in adult dogs and puppies over 6 months of age and weighing 4.4 lb. or greater.1,2 It has been tested and found safe in puppies at least 8 to 9 weeks of age at 5x the clinical dose.1,2,17 No adverse effects with Bravecto Chew for Dogs in MDR-1 gene-deficient collies at 3x the recommended dose.18

CATS

Bravecto is safe to use and efficacious in adult cats and kittens over 6 months of age and weighing 2.6. lb. or greater.3 It has been tested and found safe in kittens at least 11 to 13 weeks of age at 5x the clinical dose.3

PROVEN SAFETY

No known contraindications for Bravecto Chew for Dogs and Bravecto Topical Solution for Dogs and Cats.1-3

No problems reported in field trials in dogs and cats that received Bravecto concurrently with other commonly used medication.1-3

Bravecto has not been shown to be effective for 12 weeks1 duration in puppies or kittens less than 6 months of age. 

In field studies and safety studies, no dogs or cats experienced serious adverse events.1-3,7,8

In margin of safety study, kittens and puppies were dosed at three 8-week intervals.

Experience the 12-Week* Difference

Contact us for more information about prescribing Bravecto for the dogs and cats in your care.

Contact Sales

For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at

1-800-224-5318.

This site is intended for veterinary professionals. Visit our website for pet parents.

*BRAVECTO kills fleas and prevents flea infestations. BRAVECTO (fluralaner) Chews for Dogs kills ticks (black-legged tick, American dog tick, brown dog tick, and Asian longhorned tick) for 12 weeks. BRAVECTO Chews also kills lone star ticks for 8 weeks. BRAVECTO (fluralaner topical solution) for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks. BRAVECTO Topical Solution for Dogs also kills lone star ticks for 8 weeks. BRAVECTO (fluralaner topical solution) for Cats kills ticks (black-legged tick and Asian longhorned tick) for 12 weeks. BRAVECTO Topical Solution for Cats also kills American dog ticks for 8 weeks

IMPORTANT SAFETY INFORMATION

BRAVECTO 1-MONTH (fluralaner) Chews: indicated for dogs 8 weeks of age and older. The most commonly reported adverse reactions include itching, diarrhea, vomiting, decreased appetite, elevated ALT, lethargy, and weight loss. BRAVECTO 1-MONTH is not effective against A. americanum in puppies less than 6 months of age.  BRAVECTO (fluralaner) Chews for Dogs: The most commonly reported adverse reactions include vomiting, lethargy, diarrhea, anorexia and pruritus. In some cases, adverse events have been reported following use in breeding females. BRAVECTO (fluralaner topical solution) for Dogs:  The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash.   BRAVECTO (fluralaner topical solution) for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO Topical Solution for Cats is not effective against American dog ticks beyond 8 weeks of dosing. BRAVECTO PLUS (fluralaner and moxidectin topical solution) for Cats:  The most commonly reported adverse reactions include vomiting, hair loss, itching, diarrhea, lethargy, dry skin, elevated ALT, and hypersalivation. BRAVECTO PLUS has not been shown to be effective for 2 months in kittens less than 6 months of age.  Use with caution in cats that are heartworm positive.  The effectiveness of BRAVECTO PLUS to prevent heartworm disease after bathing or water immersion has not been evaluated. 

BRAVECTO Chews and Topical Solution for dogs have not been shown to be effective for 12-weeks’ duration in puppies or kittens less than 6 months of age. BRAVECTO Chews and Topical Solution for Dogs are not effective against the lone star tick beyond 8 weeks of dosing.  BRAVECTO Topical Solution for Dogs and Cats and BRAVECTO PLUS for Cats are for topical use only.  Avoid oral ingestion.  The safety of BRAVECTO Topical Solution for Cats and BRAVECTO PLUS have not been established in breeding, pregnant and lactating cats.

All BRAVECTO products contain fluralaner, which is a member of the isoxazoline class.  This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures.  Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.  Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. 

References: 

1. Bravecto Chew for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2014. 
2. Bravecto Topical Solution for Dogs [prescribing information]. Madison, NJ: Merck Animal Health; 2016. 
3. Bravecto Topical Solution for Cats [prescribing information]. Madison, NJ: Merck Animal Health; 2016. 
4. Rohdich N, Roepke RKA, Zschiesche E. A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto™ (fluralaner) against Frontline™ (fipronil) in flea- and tick-infested dogs. Parasites & Vectors. 2014;7:83. 
5. Beck S, Schein E, Baldermann C, von Samson-Himmelstjerna G, Kohn B. Tick infestation and tick prophylaxis in dogs in the area of Berlin/Brandenburg – results of a questionnaire study. Berl Munch Tierarztl Wochenschr. 2013;126(1-2):69-76. 
6. Kidd L, Breitschwerdt EB. Transmission times and prevention of tick-borne diseases in dogs. Compend Contin Educ Pract Vet. 2003;(25)10:742-751. 
7. Freedom of Information Summary, NADA 141-426. Approved May 15, 2014. 
8. Freedom of Information Summary, NADA 141-459. Approved 2016. 
9. Gassel M, Wolf C, Noack S, Williams H, Ilg T. The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity. Insect Biochem Mol Biol. 2014;45:111-124. 
10. Williams H, Demeler J, Taenzler J, Roepke RK, Zshiesche E, Heckeroth AR. A quantitative evaluation of the extent of fluralaner uptake by ticks (Ixodes ricinus, Ixodes scapularis) in fluralaner (Bravecto™) treated vs. untreated dogs using the parameters tick weight and coxal index. Parasites & Vectors. 2015;8:352. 
11. Taenzler J, Wengenmayer C, Williams H, et al. Onset of activity of fluralaner (Bravecto™) against Ctenocephalides felis on dogs. Parasites & Vectors. 2014;7:567. 
12. Meadows C, Guerino F, Sun F. A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling flea infestations. Parasites & Vectors. 2014;7:375. 
13. CAPCvet.org. Accessed July 5, 2016. 
14. Data on File, Merck Animal Health. 
15. Taenzler J, Liebenberg J, Roepke RKA, Heckeroth AR. Prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs treated orally with fluralaner chewable tablets (Bravecto™). Parasites & Vectors. 2015;8:305. 
16. Wengenmayer C, Williams H, Zschiesche E, et al. The speed of kill of fluralaner (Bravecto™) against lxodes ricinus ticks on dogs. Parasites & Vectors. 2014;7:525. 
17. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner chewable tablets (Bravecto™), a novel systemic antiparasitic drug, in dogs after oral administration. Parasites & Vectors. 2014;7:87. 
18. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) collies after oral administration. Parasites & Vectors. 2014;7:86. 
19. Burgio et al. Parasites & Vectors (2016) 9:626. 
20. Meadows et al, Parasites & Vectors, (2017) 10:36. 
21. Meadows et al, Parasites & Vectors, (2017) 10:37.